Takeaway
Dominant mutations in DNAJB6 inhibit myogenic signaling via enhanced glycogen synthase kinase-β (GSK3β) activity in limb-girdle muscular dystrophy 1D (LGMD1D).
Why this matters
Inhibition of GSK3β with lithium chloride (LiCl) may be of therapeutic interest in the treatment of LGMD1D.